$1.60
-1.8%Acrivon Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates. Its lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2, which is in a potentially registrational Phase 2 trial across various tumor types, including platinum-resistant ovarian, endometrial, and bladder cancer. The company is also developing its preclinical stage pipeline programs targeting critical nodes in the DNA damage response and cell cycle regulation pathways, such as WEE1, a protein kinase and PKMYT1, a protein serine/threonine kinase. The company was incorporated in 2018 and is based in Watertown, Massachusetts.
Academic Co-Founder, Head of Phosphoproteomics & Member of Scientific Advisory Board
Chief Development Officer
Compensation
$480,723
Chief Financial Officer & Principal Financial Officer
Chief Legal Officer & Corporate Secretary
Compensation
$587,108
Chief Operating Officer
Compensation
$774,026
Co-Founder, Chairman of the Board, Chief Executive Officer, President & Acting Chief Scientific Officer
Compensation
$1,068,552
Co-Founder, Executive Vice President of Business Operations, Site Head, Treasurer & Director
Compensation
$824,474
Vice President & Head of Data Science
Vice President of Finance & Accounting
Vice President of Quality & Compliance
During the last 12 months, insiders have purchased $692K and sold $32K worth of ACRV shares, resulting in $659K of net buying activity.
0
0.00
0
0.00
+0
+$0
67.8K
114.34K
0
0.00
+114K
+$114K
225.0K
407.25K
842
1.52K
+406K
+$406K
141.9K
170.31K
23.4K
30.96K
+139K
+$139K
Mirza Mansoor Raza
Officer: Chief Medical Officer
$407K
Blume-Jensen Peter
Director, Officer: President And Ceo
$82K
Shacham Sharon
Director
$24K
Palani Santhosh
Director
$24K
Magovcevic-Liebisch Ivana
Director
$24K
Blume-Jensen Peter
Director, Officer: President And Ceo
$27K
Miller Mary
Officer: Chief Legal Officer
$3K
Levy Adam D.
Officer: Chief Financial Officer
$1K
Devroe Eric
Officer: Chief Operating Officer
$852
Gamelin Erick
Officer: Chief Development Officer
$560
Strong bullish signal with $659K net buying. Insiders are aggressively accumulating shares, suggesting significant confidence in future prospects.
Exceptional buy/sell ratio. Buying dramatically outweighs selling—one of the strongest possible insider signals.
5 insider buyers and 5 sellers. Equal participation suggests mixed or neutral insider views.
Compelling insider conviction: The combination of strong buy/sell ratio and multiple buyers suggests insiders see attractive risk/reward. Consider this alongside fundamental analysis for confirmation.
ACRV - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2026 N/A | April 30, 2026 | June 17, 2026 | 2026 | |
DEF 14A DEF 14A 2025 N/A | April 25, 2025 | June 13, 2025 | 2025 | |
DEF 14A DEF 14A 2024 N/A | April 26, 2024 | June 20, 2024 | 2024 | |
DEF 14A DEF 14A 2023 N/A | May 01, 2023 | June 22, 2023 | 2023 |
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.